Compare · NRXS vs TMDX
NRXS vs TMDX
Side-by-side comparison of Neuraxis Inc. (NRXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.57B, about 30.5x NRXS ($84.2M).
- Over the past year, NRXS is up 175.9% and TMDX is down 47.2% - NRXS leads by 223.1 points.
- TMDX has hit the wire 12 times in the past 4 weeks while NRXS has been quiet.
- TMDX has more recent analyst coverage (18 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- TransMedics Group Inc.
- Price
- $6.76+1.35%
- $74.36+4.47%
- Market cap
- $84.2M
- $2.57B
- 1M return
- -18.36%
- +9.69%
- 1Y return
- +175.92%
- -47.21%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NRXS
- NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- Director Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)
- SEC Form DEFA14A filed by Neuraxis Inc.
- SEC Form DEF 14A filed by Neuraxis Inc.
- Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NeurAxis Expands Payer Coverage with Four New Medical Policies
- Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.